US lawmakers questions FDAs drug inspection programme in India and China
Tuesday, 25 June 2024
Three US lawmakers have raised concerns about the FDA's foreign drug inspection program in India and China, citing inconsistent inspection outcomes. They noted significant variability in findings, suggesting potential issues in inspector competency and thoroughness, and called for further investigation into the program's efficacy and reliability.
|
||||
|
|
||||
You Might Like💡 newsR Knowledge: Other News Mentions |
||||
